Kalbe Farma Tbk PT operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kalbe Farma Tbk PT with three other
pharmaceutical manufacturers in Asia:
Jiangsu Hengrui Medicine Co., Ltd.
sales of 9.32 billion Chinese Renmimbi [US$1.36 billion]
of which 98%
was Medicinal Manufacturing),
Cadila Healthcare Ltd
(86.51 billion Indian Rupees [US$1.28 billion]
of which 100%
was Pharmaceutical Products), and
Zhejiang Hisun Pharmaceutical, Ltd.
based in China
(8.77 billion Chinese Renmimbi [US$1.28 billion]
of which 64%
was Drug/Medicine Sales).
Kalbe Farma Tbk PT reported sales of 17.89 trillion Indonesian Rupiahs (US$1.34 billion)
December of 2015.
increase of 3.0%
versus 2014, when the company's sales were 17.37 trillion Indonesian Rupiahs.
Sales at Kalbe Farma Tbk PT have increased during each of the previous five years
(and since 2010, sales have increased a total of 75%).
Sales of Nutritionals saw an increase
that was more than double the company's growth rate: sales were up
11.6% in 2015, from
4.58 trillion Indonesian Rupiahs to 5.11 trillion Indonesian Rupiahs.
Kalbe Farma Tbk PT also saw significant increases in sales in
Consumer Health (up 4.9% to 3.07 trillion Indonesian Rupiahs)
Not all segments of Kalbe Farma Tbk PT experienced an increase in sales in 2015:
sales of Distribution and Logistics fell 2.2% to 5.41 trillion Indonesian Rupiahs.
Kalbe Farma Tbk PT also experienced decreases in sales in
Prescription Pharmaceutical (down 0.8% to 4.29 trillion Indonesian Rupiahs)